Literature DB >> 16001090

Newer antidepressants in the primary care setting.

J Sloan Manning1.   

Abstract

Because major depression has negative effects on other disease states, proper recognition and treatment of depression are important in the primary care setting. Although the perfect antidepressant does not yet exist, newer antidepressants have advanced the field. This article will summarize key features of 3 newer antidepressants that represent advances in psychopharmacology: mirtazapine, which has a dual effect on serotonergic and noradrenergic systems; escitalopram, the latest selective serotonin reuptake inhibitor, which is the first pure antidepressant stereoisomer in clinical use; and duloxetine, a dual reuptake inhibitor of norepinephrine and serotonin that is expected to be clinically available in the near future.

Entities:  

Year:  2004        PMID: 16001090      PMCID: PMC486946     

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  22 in total

Review 1.  Antidepressants as analgesics: a review of randomized controlled trials.

Authors:  M E Lynch
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

2.  Does mirtazapine have a more rapid onset than SSRIs?

Authors:  F M Quitkin; B P Taylor; C Kremer
Journal:  J Clin Psychiatry       Date:  2001-05       Impact factor: 4.384

3.  Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.

Authors:  F P Bymaster; L J Dreshfield-Ahmad; P G Threlkeld; J L Shaw; L Thompson; D L Nelson; S K Hemrick-Luecke; D T Wong
Journal:  Neuropsychopharmacology       Date:  2001-12       Impact factor: 7.853

4.  Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features.

Authors:  J D Guelfi; M Ansseau; L Timmerman; S Kørsgaard
Journal:  J Clin Psychopharmacol       Date:  2001-08       Impact factor: 3.153

5.  Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial.

Authors:  M Fava; D L Dunner; J H Greist; S H Preskorn; M H Trivedi; J Zajecka; M Cohen
Journal:  J Clin Psychiatry       Date:  2001-06       Impact factor: 4.384

6.  Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients.

Authors:  M E Thase; A A Nierenberg; M B Keller; J Panagides
Journal:  J Clin Psychiatry       Date:  2001-10       Impact factor: 4.384

7.  Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.

Authors:  E Leinonen; J Skarstein; K Behnke; H Agren; J T Helsdingen
Journal:  Int Clin Psychopharmacol       Date:  1999-11       Impact factor: 1.659

8.  Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.

Authors:  M J Owens; D L Knight; C B Nemeroff
Journal:  Biol Psychiatry       Date:  2001-09-01       Impact factor: 13.382

9.  Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

Authors:  David J Goldstein; Craig Mallinckrodt; Yili Lu; Mark A Demitrack
Journal:  J Clin Psychiatry       Date:  2002-03       Impact factor: 4.384

10.  Mirtazapine compared with paroxetine in major depression.

Authors:  O Benkert; A Szegedi; R Kohnen
Journal:  J Clin Psychiatry       Date:  2000-09       Impact factor: 4.384

View more
  1 in total

1.  Atomoxetine Used Adjunctively With Selective Serotonin Reuptake Inhibitors to Treat Depression.

Authors:  Timothy R. Berigan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.